BTIG Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Justin Zelin maintains a Buy rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and raises the price target from $34 to $35.
June 26, 2023 | 9:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Justin Zelin maintains a Buy rating on Syndax Pharmaceuticals and raises the price target from $34 to $35.
The news of BTIG maintaining a Buy rating and raising the price target for Syndax Pharmaceuticals is likely to have a positive impact on the stock price in the short term. Investors may see this as a sign of confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100